Pharmaceutical products

Tender description

This framework agreement is for the supply of unlicensed, aseptically compounded, ready to use medicines in syringe and infusion bags to NHS Scotland. The goods have been separated into four (4) categories, each of which is identified as a ‘Lot’. Full details of each lot is contained in Section II.2) of this notice. Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses: — atezolizumab, — cetuximab, — doxorubicin, — epirubicin, — infliximab (inflectra®), (remicade®), (remsima®), — pivolumab, — pembrolizumab, — pertuzumab. The authority intends awarding all presentations within this lot to a single supplier. Full details of goods and volumes can be found within the ITT. Any potential framework participant awarded to Lot 1 will not be eligible for award to Lot 2 or 3. Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses: — cyclophosphamide, — fluorouracil, — Iiinotecan, — methotrexate, — rituximab (mabthera®), (rixathon®), (truxima®). The authority intends awarding all presentations within this lot to a single supplier. Full details of goods and volumes can be found within the ITT. Any potential framework participant awarded to Lot 2 will not be eligible for award to Lot 1 or Lot 3. Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses: — bortezomib, — carboplatin, — cisplatin, — docetaxel, — gemcitabine, — oxaliplatin, — trastuzumab (herceptin®), (herzuma®), — vincristine. The authority intends awarding all presentations within this lot to a single supplier. Full details of goods and volumes can be found within the ITT. Any potential framework participant awarded to Lot 3 will not be eligible for award to Lot 1 or Lot 2. Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, the molecules included in this Lot are: — bevacizumab, — cytarabine, — infliximab (zessly®), — insulin, — methotrexate, — natalizumab, — nivolumab, — paclitaxel, — pemetrexed, — tocilizumab, — trastuzumab (kanjinti®), (ontruzant®), — trastuzumab subcutaneous, — vedolizumab. Each product line will be treated as an individual lot and awarded as an unranked multi-supplier framework. It is envisaged that each product line will be awarded to a maximum of three (3) framework participants. Full details of goods and volumes can be found within the ITT documents.